FARMINGDALE, N.Y., June 12, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo – facial surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced today that is has received a new U.S. patent on the Company's medical device products. The patent describes a means to control the output of various powered surgical devices such that power can be applied only at times where the tool is translated forward in the operative site and not at other times. By limiting power on to only the time required, tissue heating is reduced thereby improving procedure outcome and enhancing safety along with surgeon ergonomics. This action does not require the surgeon to activate switches or other mechanical means so that the action is transparent to the user.
To date this year, six patents have been issued to Misonix, many of which apply to the Company's ultrasonic platform in general and to its BoneScalpel™ product.
Michael A. McManus, Jr., President and CEO of Misonix stated, "Misonix continues to grow and protect its core technology through continued intellectual property development and patent submissions. We believe our unique application of Ultrasound technology is one of our great assets which will continue to create growth opportunities and value going forward."
About Misonix:Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Private Securities Litigation Reform Act of 1995With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and Current Reports on Form 8 K. The Company disclaims any obligation to update its forward looking relationships.Misonix Contact:
Investor Relations Contact:Richard Zaremba
Joe Diaz, Lytham Partners631-694-9555
|SOURCE Misonix, Inc.|
Copyright©2012 PR Newswire.
All rights reserved